NVSEF News and Press, Novartis Ag Basel Akt From 12/06/21

FDEU was the 2nd-ranked DxY fund in our recent Quality CEF report. FDEU achieves full distribution coverage through investment into high dividend stocks. However, value and options strategy has caused underperformance vs. benchmark. Wide discount provides an attractive entry p...

IGRO is overweight in Europe and financials. Its total return since inception is disappointing. Why I prefer VIGI and DNL. For further details see: IGRO: International Dividend Growth

VYMI strategy and portfolio. Past performance vs. competitors. Takeaway. For further details see: VYMI: International High Yield Overweight In Financials

Kahn Brothers’ 13F portfolio value increased from $698M to $710M this quarter. Pfizer, VOXX International, and ViewRay were increased substantially during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~44% of the 13F...

Fisher’s 13F portfolio value increased from ~$159B to ~$161B in Q3 2021. Advanced Micro Devices, Facebook, and Lam Research were increased while reducing Visa this quarter. The top three positions are Apple, Microsoft, and Amazon. They add up to ~14% of the portfolio. ...

On Monday, Eli Lilly And Co ( NYSE:LLY ) and Novartis AG ( OTCMKTS:NVSEF ) shares edged higher after announcing their most recent quarterly results. Eli Lilly’s revenue and earnings missed expectations while Novartis beat on earnings and matched top-line estimates. Eli Li...

Novartis AG (NVS) Q3 2021 Earnings Conference Call October 26, 2021, 08:00 AM ET Company Participants Vas Narasimhan – Chief Executive Officer Samir Shah – Global Head of Investor Relations Harry Kirsch – Chief Financial Officer Marie France – President of Novartis...

The following slide deck was published by Novartis AG in conjunction with their 2021 Q3 earnings call. For further details see: Novartis AG 2021 Q3 - Results - Earnings Call Presentation

Biogen is one of the leading providers of medicines used for the treatment of multiple sclerosis, spinal muscular atrophy. Biogen's gross margin is around 83.4%, significantly higher than the medical industry average and one of the highest among the top 20 pharmaceutical companies in ...

Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analy...